WuXi Facility Passes FDA API Manufacture Inspection

News Aug 20, 2014

This represents the first FDA inspection of STA’s facilities for the manufacture of an API. Last year, STA’s manufacturing operations passed an inspection by the FDA for the manufacture of an advanced intermediate.

STA’s integrated platform of services, extending from process research to research manufacturing to commercial manufacturing, helps the company’s clients move their new chemical entities through preclinical and clinical development to global commercial launch.

“We are very pleased to have passed a second FDA inspection of our manufacturing facilities," said Dr. Ge Li, Chairman and CEO of WuXiPharmaTech. “These favorable outcomes reflect our dedication to maintaining the highest quality standards throughout our organization.”

Fermentation Byproduct Suppresses Seizures in Nerve Agent Poisoning

News

A compound found in trace amounts in alcoholic beverages is more effective at combating seizures in rats exposed to an organophosphate nerve agent than the current recommended treatment.

PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

News

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.

Anti-Malaria Drugs Delivered With Caffeine

News

Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.